

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and Hong Kong Securities Clearing Company Limited (“HKSCC”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined, terms and expressions used in this announcement shall have the same meanings as those defined in the prospectus (the “Prospectus”) of Shanghai Bio-heart Biological Technology Co., Ltd. (the “Company”) dated December 13, 2021.

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong). This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction. The Offer Shares have not been and will not be registered under the United States Securities Act of 1933, as amended from time to time (the “U.S. Securities Act”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. There will be no public offer of the Offer Shares in the United States.



Shanghai Bio-heart Biological Technology Co., Ltd.

上海百心安生物技術股份有限公司

(A joint stock company incorporated in the People’s Republic of China with limited liability)

(Stock Code: 2185)

**STABILIZING ACTIONS, END OF STABILIZATION PERIOD AND
LAPSE OF OVER-ALLOTMENT OPTION**

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company announces that the stabilization period in connection with the Global Offering ended on Saturday, January 15, 2022, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. No stabilization action was carried out by the Stabilizing Manager in relation to the Global Offering during the stabilization period.

LAPSE OF OVER-ALLOTMENT OPTION

The Sole Global Coordinator (acting in such capacity and as the Underwriter) did not exercise the Over-allotment Option during the stabilization period and the Over-allotment Option lapsed on Saturday, January 15, 2022. Accordingly, no shares were or will be issued under the Over-allotment Option.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company announces that the stabilization period in connection with the Global Offering ended on Saturday, January 15, 2022, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. No stabilization action was carried out by the Stabilizing Manager in relation to the Global Offering during the stabilization period.

LAPSE OF OVER-ALLOTMENT OPTION

The Sole Global Coordinator (acting in such capacity and as the Underwriter) did not exercise the Over-allotment Option during the stabilization period and the Over-allotment Option lapsed on Saturday, January 15, 2022. Accordingly, no shares were or will be issued under the Over-allotment Option.

PUBLIC FLOAT

Immediately after the end of the stabilization period, the number of Shares in public hands will continue to represent no less than 25% of the total issued share capital of the Company which satisfies the minimum percentage prescribed in Rule 8.08(1)(a) of the Listing Rules.

By order of the Board
Shanghai Bio-heart Biological Technology Co., Ltd.
Philip Li WANG
Chairman and executive director

Hong Kong, Monday, January 17, 2022

As at the date of this announcement, the Board of the Company comprises Mr. Philip Li WANG as chairman and executive director, Mr. Yunqing WANG as executive director, Ms. Li CAI, Mr. Quan ZHOU, Mr. Ji CHEN and Mr. Jie YIN as non-executive directors, and Mr. Charles Sheung Wai CHAN, Mr. Xubo LU and Mr. George Chien Cheng LIN as independent non-executive directors.